Active Ingredient History
Urelumab is a fully human, non‐ligand binding, CD137 agonist immunoglobulin‐γ 4 (IgG4) monoclonal antibody. It was developed utilizing Medarex's UltiMAb(R) technology by Bristol-Myers Squibb for the treatment of cancer and solid tumors. Urelumab promotes anti-tumor immunity, or an immune response against tumor cells, via CD137 activation. The application of Urelumab has been limited due to the fact that it can cause severe liver toxicity. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Colorectal Neoplasms (Phase 1)
Glioblastoma (Phase 1)
Gliosarcoma (Phase 1)
Head and Neck Neoplasms (Phase 1)
Leukemia (Phase 2)
Leukemia, B-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1)
Neoplasms (Phase 1/Phase 2)
Skin Neoplasms (Early Phase 1)
Urinary Bladder Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue